Notable Labs, Ltd. Overview
Pro stress-test →Notable Labs is a personalized testing service for cancer patients that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor without a clinical trial. The company operates a platform that bio-simulates cancer treatment responses at the cellular level to predict patient-specific drug efficacy.
Strategic Profile
Pro stress-test →The company began public trading on NASDAQ under symbol NTBL in October 2023, following a merger with VBL Therapeutics, and is focusing on advancement of its proprietary Predictive Precision Medicines Platform (PPMP) with a therapeutic pipeline focused on cancer patients, particularly acute myeloid leukemia (AML). Notable Labs targets patients with cancer, particularly those with acute myeloid leukemia, aiming to improve treatment outcomes by identifying responsive patient subsets.
Competitive Landscape
Pro stress-test →Notable Labs competes in the precision oncology and biotech drug discovery space alongside companies like Verge Genomics and AbCellera Biologics. The company's AI-driven patient-matching platform differentiates it from traditional oncology drug developers, positioning it as a niche player in rare hematologic malignancies rather than a direct competitor to large pharmaceutical companies.
Industry Context
Notable Labs, Ltd. operates in Precision oncology AI platforms.
Key facts
Founded: 2014 · Headquarters: Foster City, CA, United States · Employees: 31 · Revenue: $313K (TTM as of June 2024) · Market cap: $966K (as of December 30, 2025)